

LC-MS-Based Urinary Metabolite Signatures in Idiop

Journal of Proteome Research

14, 467-478

DOI: [10.1021/pr500807t](https://doi.org/10.1021/pr500807t)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson's disease. <i>Scientific Reports</i> , 2015, 5, 13888.	1.6	116
2	Urinary Biomarkers of Brain Diseases. <i>Genomics, Proteomics and Bioinformatics</i> , 2015, 13, 345-354.	3.0	110
3	Recent Advances in Proteomics Applied to Elucidate the Role of Environmental Impacts on Human Health and Organismal Function. <i>Journal of Proteome Research</i> , 2015, 14, 1-4.	1.8	1
4	Association between Oxidative DNA Damage and Risk of Colorectal Cancer: Sensitive Determination of Urinary 8-Hydroxy-2'-deoxyguanosine by UPLC-MS/MS Analysis. <i>Scientific Reports</i> , 2016, 6, 32581.	1.6	102
5	Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting. <i>Bioanalysis</i> , 2016, 8, 2497-2518.	0.6	16
6	Normalization and integration of large-scale metabolomics data using support vector regression. <i>Metabolomics</i> , 2016, 12, 1.	1.4	134
7	Metabolic changes may precede proteostatic dysfunction in a <i>Drosophila</i> model of amyloid beta peptide toxicity. <i>Neurobiology of Aging</i> , 2016, 41, 39-52.	1.5	14
8	A metabolomics strategy to explore urinary biomarkers and metabolic pathways for assessment of interaction between Danhong injection and low-dose aspirin during their synergistic treatment. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1026, 168-175.	1.2	8
9	Metabolomic biomarkers as strong correlates of Parkinson disease progression. <i>Neurology</i> , 2017, 88, 862-869.	1.5	113
10	metabolic profiling of Parkinson's disease and mild cognitive impairment. <i>Movement Disorders</i> , 2017, 32, 927-932.	2.2	58
11	Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia. <i>Journal of Neurochemistry</i> , 2017, 142, 756-766.	2.1	83
12	Metabolomics for the masses: The future of metabolomics in a personalized world. <i>European Journal of Molecular and Clinical Medicine</i> , 2017, 3, 294.	0.5	99
13	NOREVA: normalization and evaluation of MS-based metabolomics data. <i>Nucleic Acids Research</i> , 2017, 45, W162-W170.	6.5	305
14	Methods for studying the metabolic basis of <i>Drosophila</i> development. <i>Wiley Interdisciplinary Reviews: Developmental Biology</i> , 2017, 6, e280.	5.9	25
15	Decreased long-chain acylcarnitines from insufficient β -oxidation as potential early diagnostic markers for Parkinson's disease. <i>Scientific Reports</i> , 2017, 7, 7328.	1.6	95
16	Biomarker Research in Parkinson's Disease Using Metabolite Profiling. <i>Metabolites</i> , 2017, 7, 42.	1.3	107
17	Metabolic Reprogramming in Amyotrophic Lateral Sclerosis. <i>Scientific Reports</i> , 2018, 8, 3953.	1.6	69
18	Potential biomarkers of Parkinson's disease revealed by plasma metabolic profiling. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1081-1082, 101-108.	1.2	82

#	ARTICLE	IF	CITATIONS
19	Targeting human urinary metabolome by LC-MS/MS: a review. <i>Bioanalysis</i> , 2018, 10, 489-516.	0.6	42
20	Predictive Role of Urinary Metabolic Profile for Abnormal MRI Score in Preterm Neonates. <i>Disease Markers</i> , 2018, 2018, 1-9.	0.6	10
21	What Is the Evidence that Parkinson's Disease Is a Prion Disorder, Which Originates in the Gut?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3573.	1.8	39
22	Large-Scale Longitudinal Metabolomics Study Reveals Different Trimester-Specific Alterations of Metabolites in Relation to Gestational Diabetes Mellitus. <i>Journal of Proteome Research</i> , 2019, 18, 292-300.	1.8	33
23	A novel malic acid-enhanced method for the analysis of 5-methyl-2-deoxycytidine, 5-hydroxymethyl-2-deoxycytidine, 5-methylcytidine and 5-hydroxymethylcytidine in human urine using hydrophilic interaction liquid chromatography-tandem mass spectrometry. <i>Analytica Chimica Acta</i> , 2018, 1034, 110-118.	2.6	38
24	Promising Metabolite Profiles in the Plasma and CSF of Early Clinical Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 51.	1.7	74
25	Towards an Integrative Understanding of tRNA Aminoacylation-Diet-Host-Gut Microbiome Interactions in Neurodegeneration. <i>Nutrients</i> , 2018, 10, 410.	1.7	17
26	Raman Spectroscopy to Diagnose Alzheimer's Disease and Dementia with Lewy Bodies in Blood. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2786-2794.	1.7	62
27	Metabolome Analysis. , 2019, , 463-475.		9
28	Bacterial Metabolites Mirror Altered Gut Microbiota Composition in Patients with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, S359-S370.	1.5	31
29	Discovery of Gut Bacteria Specific to Alzheimer's Associated Diseases is a Clue to Understanding Disease Etiology: Meta-Analysis of Population-Based Data on Human Gut Metagenomics and Metabolomics. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 319-355.	1.2	25
30	The Potential of Carnosine in Brain-Related Disorders: A Comprehensive Review of Current Evidence. <i>Nutrients</i> , 2019, 11, 1196.	1.7	68
31	Analytical methods used in the study of Parkinson's disease. <i>TrAC - Trends in Analytical Chemistry</i> , 2019, 118, 292-302.	5.8	9
32	Diet-Related Metabolic Perturbations of Gut Microbial Shikimate Pathway-Tryptamine-tRNA Aminoacylation-Protein Synthesis in Human Health and Disease. <i>International Journal of Tryptophan Research</i> , 2019, 12, 117864691983455.	1.0	24
33	Recent advances and perspectives of metabolomics-based investigations in Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2019, 14, 3.	4.4	176
34	Mass spectrometry-based metabolomics: Targeting the crosstalk between gut microbiota and brain in neurodegenerative disorders. <i>Mass Spectrometry Reviews</i> , 2019, 38, 22-33.	2.8	131
35	Phenylalanine 4-monooxygenase: the α -sulfoxidation polymorphism. <i>Xenobiotica</i> , 2020, 50, 51-63.	0.5	5
36	Three-Dimensional Graphene Enhances Neural Stem Cell Proliferation Through Metabolic Regulation. <i>Frontiers in Bioengineering and Biotechnology</i> , 2019, 7, 436.	2.0	41

#	ARTICLE	IF	CITATIONS
37	Circulating Metabolites as Potential Biomarkers for Neurological Disordersâ€™Metabolites in Neurological Disorders. <i>Metabolites</i> , 2020, 10, 389.	1.3	18
38	The use of animal models in metabolomics. , 2020, , 123-136.		1
39	Simultaneous Determination of Eight Urinary Metabolites by HPLC-MS/MS for Noninvasive Assessment of Traumatic Brain Injury. <i>Journal of the American Society for Mass Spectrometry</i> , 2020, 31, 1910-1917.	1.2	6
40	Identification of potential urine biomarkers in idiopathic parkinson's disease using NMR. <i>Clinica Chimica Acta</i> , 2020, 510, 442-449.	0.5	23
41	Gut metagenomics-derived genes as potential biomarkers of Parkinsonâ€™s disease. <i>Brain</i> , 2020, 143, 2474-2489.	3.7	72
42	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Induced Parkinsonâ€™s Disease in Mouse: Potential Association between Neurotransmitter Disturbance and Gut Microbiota Dysbiosis. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3366-3376.	1.7	25
43	Blood Exosomes Have Neuroprotective Effects in a Mouse Model of Parkinsonâ€™s Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-14.	1.9	20
44	Kynurenine pathway in Parkinson's diseaseâ€™An update. <i>ENeurologicalSci</i> , 2020, 21, 100270.	0.5	50
45	Overview of Brain-to-Gut Axis Exposed to Chronic CNS Bacterial Infection(s) and a Predictive Urinary Metabolic Profile of a Brain Infected by <i>Mycobacterium tuberculosis</i> . <i>Frontiers in Neuroscience</i> , 2020, 14, 296.	1.4	12
46	Integrated Metabolomics and Proteomics Analysis Reveals Plasma Lipid Metabolic Disturbance in Patients With Parkinsonâ€™s Disease. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 80.	1.4	41
47	Common gene expression signatures in Parkinsonâ€™s disease are driven by changes in cell composition. <i>Acta Neuropathologica Communications</i> , 2020, 8, 55.	2.4	38
48	Metabolomics analysis of microbiota-gut-brain axis in neurodegenerative and psychiatric diseases. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 194, 113681.	1.4	56
49	Targeted metabolomics analysis of postoperative delirium. <i>Scientific Reports</i> , 2021, 11, 1521.	1.6	24
50	Diseases & Disorders Metabolomics: An Emerging Platform for Treatment and Diagnosis in Human Disease. , 2021, , 435-451.		0
52	Metabolomics in Parkinson's disease. <i>Advances in Clinical Chemistry</i> , 2021, 104, 107-149.	1.8	7
53	The Role of Gut Bacterial Metabolites in Brain Development, Aging and Disease. <i>Nutrients</i> , 2021, 13, 732.	1.7	90
54	Clinical Insights into Mitochondrial Neurodevelopmental and Neurodegenerative Disorders: Their Biosignatures from Mass Spectrometry-Based Metabolomics. <i>Metabolites</i> , 2021, 11, 233.	1.3	10
55	A UPLC-Q-TOF/MS-Based Metabolomics Study on the Effect of <i>Corallodiscus flabellatus</i> (Craib) B. L. Burt Extract on Alzheimerâ€™s Disease. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 1-11.	0.5	1

#	ARTICLE	IF	CITATIONS
56	The Footprint of Kynurenine Pathway in Neurodegeneration: Janus-Faced Role in Parkinson's Disorder and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6737.	1.8	24
57	Individual variability in human urinary metabolites identifies age-related, body mass index-related, and sex-related biomarkers. <i>Molecular Genetics & Genomic Medicine</i> , 2021, 9, e1738.	0.6	5
58	Prognostic biomarkers of Parkinson's disease in the Spanish EPIC cohort: a multiplatform metabolomics approach. <i>Npj Parkinson's Disease</i> , 2021, 7, 73.	2.5	23
59	Pursuing Multiple Biomarkers for Early Idiopathic Parkinson's Disease Diagnosis. <i>Molecular Neurobiology</i> , 2021, 58, 5517-5532.	1.9	5
60	Fluorescent Nanozeolite Receptors for the Highly Selective and Sensitive Detection of Neurotransmitters in Water and Biofluids. <i>Advanced Materials</i> , 2021, 33, e2104614.	11.1	9
61	The Metabolomic Approach Reveals the Alteration in Human Serum and Cerebrospinal Fluid Composition in Parkinson's Disease Patients. <i>Pharmaceuticals</i> , 2021, 14, 935.	1.7	13
63	Comprehensive metabolic profiling of Parkinson's disease by liquid chromatography-mass spectrometry. <i>Molecular Neurodegeneration</i> , 2021, 16, 4.	4.4	86
65	Serum amino acid profile in patients with Parkinson's disease. <i>PLoS ONE</i> , 2018, 13, e0191670.	1.1	65
66	Metabolic alterations in plasma from patients with familial and idiopathic Parkinson's disease. <i>Aging</i> , 2020, 12, 16690-16708.	1.4	32
67	Discriminating patients with early-stage breast cancer from benign lesions by detection of oxidative DNA damage biomarker in urine. <i>Oncotarget</i> , 2017, 8, 53100-53109.	0.8	22
68	Urinary Metabolomics Reveals Alterations of Aromatic Amino Acid Metabolism of Alzheimer's Disease in the Transgenic CRND8 Mice. <i>Current Alzheimer Research</i> , 2016, 13, 764-776.	0.7	25
69	Serum Autoantibodies as Biomarkers for Parkinson's Disease: Background and Utility. <i>AIMS Medical Science</i> , 2015, 2, 316-327.	0.2	5
70	Urinary Biomarkers for Neurodegenerative Diseases. <i>Experimental Neurobiology</i> , 2020, 29, 325-333.	0.7	25
71	Metabolomic in Parkinson's. <i>NeuroMethods</i> , 2022, , 181-213.	0.2	0
72	Trimester-specific urinary metabolome alterations associated with gestational diabetes mellitus: A study in different pregnancy stages. <i>Chinese Chemical Letters</i> , 2022, 33, 3139-3143.	4.8	4
73	A six-metabolite panel as potential blood-based biomarkers for Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 94.	2.5	19
74	High-coverage metabolomics uncovers microbiota-driven biochemical landscape of interorgan transport and gut-brain communication in mice. <i>Nature Communications</i> , 2021, 12, 6000.	5.8	68
76	Metabolomics in degenerative brain diseases. <i>Brain Research</i> , 2021, 1773, 147704.	1.1	9

#	ARTICLE	IF	CITATIONS
77	GC-MS Based Metabolic Profiling of Parkinsonâ€™s Disease with Glutathione S-transferase M1 and T1 Polymorphism in Tunisian Patients. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2020, 23, 1041-1048.	0.6	5
78	Molecular Probes, Chemosensors, and Nanosensors for Optical Detection of Biorelevant Molecules and Ions in Aqueous Media and Biofluids. <i>Chemical Reviews</i> , 2022, 122, 3459-3636.	23.0	171
79	Predictive Modeling of Alzheimerâ€™s and Parkinsonâ€™s Disease Using Metabolomic and Lipidomic Profiles from Cerebrospinal Fluid. <i>Metabolites</i> , 2022, 12, 277.	1.3	9
80	In vitro and in vivo NMR based metabolomics in Parkinson's disease. <i>Journal of Magnetic Resonance Open</i> , 2022, 10-11, 100050.	0.5	3
92	A Set of Reliable Samples for the Study of Biomarkers for the Early Diagnosis of Parkinson's Disease. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	5
93	Medical Bioanalytics: Separation Techniques in Medical Diagnostics of Neurological Diseases and Disorders on Selected Examples. , 2022, , 49-66.		0
94	Non-Invasive Nasal Discharge Fluid and Other Body Fluid Biomarkers in Alzheimerâ€™s Disease. <i>Pharmaceutics</i> , 2022, 14, 1532.	2.0	3
95	Gut microenvironmental changes as a potential trigger in Parkinsonâ€™s disease through the gutâ€“brain axis. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	25
96	The Involvement of Kynurenine Pathway in Neurodegenerative Diseases. <i>Current Neuropharmacology</i> , 2023, 21, 260-272.	1.4	4
97	Dynamic changes in metabolites of the kynurenine pathway in Alzheimerâ€™s disease, Parkinsonâ€™s disease, and Huntingtonâ€™s disease: A systematic Review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
98	qShot MALDI analysis: A rapid, simple, convenient, and reliable quantitative phospholipidomics approach using MALDI-TOF/MS. <i>Talanta</i> , 2023, 254, 124099.	2.9	2
99	Diagnostic metabolomic profiling of Parkinson's disease biospecimens. <i>Neurobiology of Disease</i> , 2023, 177, 105962.	2.1	6
100	Human genome or human microbiome genes: Which one is more important for human health and intellectual abilities?. , 2023, , 207-239.		0
101	Inhibition of carnitine palmitoyl-transferase 1 is a potential target in a mouse model of Parkinsonâ€™s disease. <i>Npj Parkinson's Disease</i> , 2023, 9, .	2.5	3
102	Colonic diverticular disease as a risk factor for neurodegenerative and associated diseases. , 2023, , 267-289.		0
103	Serotonin syndrome in neurodegenerative diseases and COVID-19: Mechanisms and consequences of intestinal infection. , 2023, , 325-343.		0
104	Urine biomarkers discovery by metabolomics and machine learning for Parkinson's disease diagnoses. <i>Chinese Chemical Letters</i> , 2023, 34, 108230.	4.8	0
105	Changes in Liver Lipidomic Profile in G2019S-LRRK2 Mouse Model of Parkinsonâ€™s Disease. <i>Cells</i> , 2023, 12, 806.	1.8	2

#	ARTICLE	IF	CITATIONS
108	Metabolomics in the Study of Human Mitochondrial Diseases. , 2023, , 147-171.		0
109	Metabolomics in Autoimmunity, Infections, and Physiological Diseases. , 2023, , 209-239.		0